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Genomic research and the cancer clinic: uncertainty and
expectations in professional accounts
Anne Kerra*, Julia Swallowa, Choon Key Chekara and
Sarah Cunningham-Burleyb
aSchool of Sociology and Social Policy, University of Leeds, Leeds, UK; bThe Usher
Institute, University of Edinburgh, Edinburgh, UK
This paper explores clinicians’ and scientists’ accounts of genomic research in
cancer care and the complexities and challenges involved with delivering this
work. Contributing to the sociology of (low) expectations, we draw on
sociological studies of uncertainty in medicine to explore their accounts of
working with uncertainty as part of the management of patient and
institutional expectations. We consider their appeals to the importance of
modest inquiry and framing of the uncertainties of genomic medicine as
normal and at times welcome as they sought to conﬁgure professional
autonomy and jurisdictions and cultivate an experimental ethos amongst
their patients. We argue that these types of uncertainty work [Star,
S. L. 1985. “Scientiﬁc Work and Uncertainty.” Social Studies of Science 15
(3): 391–427] are a key feature of managing expectations at the intersections
of genomic research and clinical care.
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Introduction
Genomics is at the forefront of contemporary efforts to develop and deliver person-
alized medicine. This complex landscape of Whole Genome Sequencing (WGS),
molecular proﬁling, adaptive trials and targeted treatments is associated with a
range of transformative healthcare agendas to personalize diagnosis, care and treat-
ment for major diseases like cancer (Beck and Ng 2014). Across the UK, the
National Health Service (NHS) and research funders such as Cancer Research
UK, working with commercial partners such as Illumina, have invested in a
range of research programmes aimed at mainstreaming genomic medicine in
cancer care – this includes Genomics England and its ﬂagship 100,000 Genomes
Project which aims to, “create a new genomic medicine service for the NHS – trans-
forming the way people are cared for” (Genomics England 2018). The CRUK
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Stratiﬁed Medicine Programme is another “pioneering initiative” which aims to
bring the “beneﬁts of genetic testing to lung cancer patients and researchers
across the UK” (Cancer Research UK, 2018).
The promise of genomics is, however, tempered by a range of concerns about its
transformative potential. Debates about new trial methodologies, measures of efﬁ-
cacy, stewardship and analysis of data, and how to ﬁnance genomic medicine can
be found across professional literatures (e.g. Conti et al. 2010; Hood and Friend
2011; Faulkner et al. 2012). Concerns about the “genohype” (Kakuk 2006) associ-
ated with genomic medicine are also apparent, particularly with respect to the
dangers of over-inﬂated politically-driven promises set against difﬁculties of
implementation in complex and often ﬁnancially challenged health services like
the NHS (Samuel and Farsides 2018) (see also Petersen and Krisjansen 2015;
Marcon, Bieber, and Caulﬁeld 2018).
Innovative health technologies have long been associated with ebullient dis-
courses of promise and optimism. The sociology of expectations has documented
the ways in which these claims help to advance innovation, recruiting commercial,
institutional and patient support and building interdisciplinary agendas (Wain-
wright et al. 2006; Tutton 2011; Pickersgill 2011; Broer and Pickersgill 2015;
Gardner, Samuel, and Williams 2015). This research has also shown that
lowered expectations and ambivalence have a role in these processes. Toggling
between promissory and pessimistic scenarios maintains innovative momentum
in biotechnology (Tutton 2011). And, as Gardner, Samuel, and Williams (2015,
998) have argued, “recalibrating” patient expectations to be “tainted with uncer-
tainty” during this process of enrollment in an innovative alliance.
In this paper, we contribute to this sociology of (low) expectations by exploring
how scientists and clinicians account for uncertainty in relation to the expectations
of genomic research in the cancer clinic. We investigate where and how uncertain-
ties feature in professional accounts of their efforts to deliver genomic research in
cancer care and their engagements with patients, institutions and other pro-
fessionals in the process. To develop our analysis, we draw from medical sociology
and STS literatures on uncertainty (e.g. Fox 1980; Timmermans and Angell 2001;
Street 2011), focusing on how the development of “scientiﬁc medicine” uncovers
and creates uncertainties which have to be managed as part of routine professional
practice. As Fox (1980) notes, being a doctor involves cultivating ways of thinking
and coping with uncertainty, including a sense of the limits of one’s knowledge and
knowledge in the ﬁeld. Calibrating uncertainties in patient-practitioner interactions
is also key to professional autonomy and jurisdictions. New technologies and pro-
tocols promising increased certainty can disrupt these processes. For example, as
initiatives such as Evidence Based Medicine (EBM) have been taken up in medi-
cine, social scientists have shown how new paradigms based around meta-analysis
of biomedical data to generate standardized protocols can sit in tension with more
patient-centered rationalities and clinical autonomy (Armstrong 2002), especially
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in ﬁelds with a commitment to “experimental intervention,” e.g. for terminally ill
patients (Broom, Adams, and Tovey 2009).
Uncertainty can also be understood as having “generative potential” in biomedi-
cal research ﬁelds such as autism research (Hollin 2017) and exome sequencing for
the genetic causes of disease (Timmermans, Tietbohl, and Skaperdas 2017). Hollin
(2017, 225) argues that this kind of “uncertainty work” (Star 1985) makes “research
doable and failures comprehensible” thereby maintaining expectations and invest-
ment in the possibilities of future advances in the ﬁeld. Street (2011) argues that
uncertainty is a “valuable resource,” creating opportunities for new forms of exper-
tise and practice. Similarly, Moreira, May, and Bond (2009) demonstrate that
uncertainty is part of collectivizing the work of experts and cultivating “regimes
of care” (Moreira 2010) around novel diagnostic technologies for complex life lim-
iting diseases like Alzheimer’s (see also Swallow 2017).
These literatures situate uncertainty as an intrinsic feature of medical and bio-
medical practice, operating across clinician-patient, professional and institutional
boundaries and jurisdictions. This suggests the need for a closer look at how
medical and scientiﬁc professionals negotiate the uncertainties of genomic
research in cancer as part of efforts to manage expectations in the clinic and
the institution, not least because of the promise of precision. How do they
approach the potential of genomic research to offer more deﬁnitive diagnosis
and effective treatments for (some kinds of) cancer? What are their experiences
and perspectives on the implications of these new forms of knowledge for reach-
ing a more precise diagnosis/treatment nexus and managing patient expectations?
What new opportunities and challenges do the uncertainties of genomic research
offer for professional practice?
In this paper we explore these questions by drawing on interviews with a range
of cancer professionals involved with genomic initiatives as part of their clinical
and scientiﬁc practice We consider their accounts of the uncertainties involved in
genomic research and their consequences in cancer medicine, particularly in
relation to interpreting and sharing personalized molecular results with other prac-
titioners and patients.
Methods
As part of a large multi-sited research project into the implications of cancer geno-
mics for patients, we interviewed 25 practitioners involved with molecular cancer
research and diagnosis/treatments for cancer patients in the North of England about
their perspectives and experiences of genomic research and its impact on patient
care. Interviews provided important insights into how uncertainties are accounted
for and understood by practitioners, allowing practitioners a space for critical
reﬂection about their work and its meaning. We note, however, that these accounts
offer a partial and incomplete account of experiences and perspectives and do not
offer direct insights into how uncertainties unfolded across labs and clinics as part
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of everyday practice. We are therefore careful to approach these accounts as situ-
ated and contingent (Clarke, Friese, and Washburn 2016).
The practitioners we interviewed worked at one of the large teaching hospitals in
the region. Fifteen of them were involved with one (in some cases two*) large
national genomic research programmes for cancer patients that we followed as
part of our research. The ﬁrst programme was a large-scale sequencing project,
focused on service transformation to enable the NHS to provide molecular proﬁling
as standard of care in cancer services. Cancer patients were being recruited for
Whole Genome Sequencing of their tumor and healthy cells though no results
had been fed back to patients during our research. The second programme was
an observational pre-screening study of lung cancer patients, which determined eli-
gibility for entry into a non-randomized multi-treatment arm clinical trial.
The remaining participants (10) were not directly involved in recruiting patients
or analysing material as part of these two research programmes but had either
engaged with their development and implications as part of their work and/or
efforts were being made to involve their departments in one of these programmes.
Participants included ﬁve scientists (one cytogeneticist, one clinical scientist, one
histopathologist, one trainee health scientist (genetics), one clinical bioinformati-
cian), three nurses (one clinical trials assistant, one nurse consultant, one research
nurse), two genetic counselors and 15 doctors (one consultant geneticist, six oncol-
ogists, four pathologists, one clinician scientist, two physicians and one clinical
director for a genomic medicine research programme). As part of their work in
the hospital these participants were also involved in a range of other genomic
studies, trials and/or molecular testing for cancer (see Table below).
Large scale sequencing
project (5 + 2)
Molecular testing programme
and ﬂexible clinical trial (10) Other (10)
Genetic counselor 1
Genetic counselor 2
Consultant geneticist
Nurse consultant
Clinical director of
regional center
Cytogeneticist
Clinical Trials Assistant
Research nurse
Oncologist 1*
Oncologist 4
Oncologist 5
Oncologist 7
Pathologist 1 (local PI)
Pathologist 2*
Pathologist 4
Consultant Physician 2
Clinician Scientist
Oncologist 2 – molecular
proﬁling
trials
Oncologist 6 – clinical director
research facility
Trainee Oncologist – special
interest in genomics
Consultant Physician
Pathologist 3
Clinical scientist
Histopathologist
Trainee health scientist (genetics)
Clinical Bioinformatician
We spoke to interviewees about their perspectives and experiences of large-scale
genomic research initiatives and developments in cancer care, focussing especially
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on the implications for patients, services and professional practice. Interviews were
semi-structured and lasted between 30 min and 1 h; they were recorded and tran-
scribed verbatim. Ethical approval was granted by the University research ethics
committee (reference number: AREA 15-108). Using situational analysis
(Clarke, Friese, and Washburn 2016) to explore practitioners’ framing of uncertain-
ties about the meaning and implications of genomic research, we identiﬁed three
main themes across the transcripts: (i) the complexity of cancer biology (ii) how
this complexity relates to handling uncertainty when providing results to referring
clinicians (iii) difﬁcult conversations with patients. After introducing interviewees’
perceptions of the challenges of genomic medicine in cancer in the institution in
order to set the scene for a more in-depth discussion of uncertainties, we go on
to explore each of these themes in turn below.
Mainstreaming genomic medicine for cancer: challenges and ambivalence
The practitioners we interviewed were working in the context of ongoing efforts to
transform cancer services through genomics, with considerable local and national
tensions around resources, infrastructures and delivery of ambitious recruitment
targets (see also Day et al. 2017). Increasingly expected to work across departmen-
tal, disciplinary and institutional boundaries, interviewees were negotiating a range
of new demands on their time, resources and expertise. Those working in labora-
tory or genetic services were also experiencing service transformations as part of
one of the programmes we studied, which sought to centralize their activities at
a regional level; technological infrastructures (particularly IT) were under strain,
and new expectations around the collection, preparation, storage and sharing of
tissue and data were also placing additional pressures on their service and how
they worked with clinical colleagues. Clinicians working directly with patients
were also facing a range of challenges around the level of resources, patient
demand and staff shortages. The complexity of the consenting and analysis pro-
cedures for these programmes were also placing pressure on their workloads and
expertise, and there was a sense amongst many of the people we interviewed
that their hospital was in deﬁcit because it was not meeting recruitment expec-
tations for both these studies, as compared with other centers (see also Samuel
and Farsides 2018).
Although interviewees expressed considerable enthusiasm and support for
genomic research because of the more precise diagnostics and tailored treatments
this might afford, years of service reorganization and underfunding have also
created a culture of lowered expectations about new initiatives, with several ques-
tioning if these initiatives were the “latest fashion accessory” or “pet politician’s
project” which would not deliver on its promises. There were considerable
doubts about whether targeted treatments would be affordable in practice and
about the fairness of resource allocation to expensive medicines for cancer as com-
pared with other priorities, such as the prevention of cancer.
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The uncertainties of cancer and genomics
Genomic research, then, was associated with a sense of inﬂated expectations about
professional and institutional capacities and obligations to deliver service trans-
formation which meant our interviewees were cautious about its potential impact
on their practice and patients. In their accounts of wariness around these new initiat-
ives, some professionals highlighted the uncertainties of WGS and its usefulness in
the clinic as part of their justiﬁcation for lowered and lowering expectations, as we
now go on to explore.
One way in which this happened was with interviewees querying the usefulness
of WGS to identify genomic mutations (as opposed to expression proﬁling) to deli-
vering targeted treatments, as one oncologist not involved in recruitment for the
genomic medicine initiatives in his institution argued:
As a breast cancer doctor, we are lucky in having the two most important
targeted therapies in cancer by a million miles – Tamoxifen and Herceptin. Tamox-
ifen, you do not test for genetic mutations, you check for expression. With Herceptin
you do not test for mutations, you test for expression. So that puts me at the start as
being in a sceptical position about the role of genetic mutations…And in genomics
as it is currently you don’t need whole genome sequencing, you don’t need a Geno-
mics Medicine Centre, you don’t need any of the things in which there is huge com-
mercial interest and government pressure to develop, to look for expression… .
(Oncologist 6)
This sense of caution about the clinical utility of WGS was a recurrent theme in
interviews. As another oncologist put it: “whilst some of it is close to prime time
some of it is actually quite exploratory. But… there’s a danger of selling people
a dream that won’t be a reality for them” (Oncologist 1).
This danger of over-promising based on the limited clinical utility of WGS was also
articulated in accounts of genomics increasing rather than decreasing uncertainty
because it produced too much data too quickly, challenging trial methodologies
to establish the effectiveness of therapies. For example, as one oncologist specia-
lizing in lung cancer noted,
… the speed is quicker almost than you can actually do the studies to deﬁne the role of
the new molecular treatments because they tend to be rarer and rarer as you go down
the line and then how do you actually do a study when you have… in a centre like
this, just ten patients, it’s going to be difﬁcult to do the gold-standard test of any treat-
ment in a randomised control trial. So… the ability to detect new genes is ahead of
the ability to test the therapies for those new genes. So, as I say, it’s a bit bewildering.
(Oncologist 5)
A similar framing was also apparent in this interview with a genetic counselor
working as part of one of the genomic initiatives we studied, who expressed
concern about the capacity to report genomic results with certainty to cancer
patients in the future:
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… genetic counselling is woolly enough as it is, often with risks…we obviously
have to tell patients… I’m not going to go in and pretend that we know everything
about genetics, I certainly don’t now and I can’t imagine I will do once genomics
becomes more routine. I think if anything… the more we discover the more we
realise what we don’t know in some ways. (Genetic Counsellor 1)
This sense of proliferating uncertainty was associated with a framing of genomics
as revealing of inﬁnite layers of complexity, echoed below in an excerpt from an
interview with a pathologist working in a multi-disciplinary service for haematolo-
gical cancers that has already incorporated genomic analysis into its practice:
…we keep ﬁnding more but every time we unravel another layer there’s another layer
underneath… I’ve lived through maybe three or four iterations of ‘this is the test
that’s going to make everything else redundant’ … next generation sequencing is
now the next great white hope that’s going to be giving us all the information that
we need but… tumours are amazing things…we’ve just talked about resistance
… so they may well keep developing resistance and it may be involving things
other than the speciﬁc genetic mutations…we’ll constantly be running, chasing to
catch up. We may eventually get there. (Pathologist 3)
Here uncertainty was presented as endemic to the pursuit of scientiﬁc knowledge
and the need for caution about the “latest” revolutionary technology was invoked.
Querying the promise of precision and the prospects of service transformation,
these professionals performed a medico-scientiﬁc ethos of persistent but modest
inquiry redolent of the “acceptance of medical uncertainty” and the “positive phil-
osophy-of-doubting” (Fox 1980, 7) described in Fox’s landmark study of Ward F-
Second (the metabolic research ward of the Peter Bent Brigham Hospital in Boston)
([1959] 1974). Their accounts, from different clinical and laboratory positions,
mobilized uncertainty as a reason to lower expectations around genomic medicine,
but not to give up on it entirely – “Wemay eventually get there.” Reﬂecting on their
experiences with various cancers, treatments, trials, results and tests, practitioners
framed uncertainty as endemic, necessitating scepticism about promises of precise
diagnosis and effective targeted treatments.
We can also identify a similar narrative in the accounts of nurses involved with
these genomic research initiatives, echoing the point above by the pathologist about
uncertainties arising because of the sheer complexity of cancer tumors. Nurses
negotiating difﬁcult and complex consent and tissue collection procedures spoke
about genomic research being one part of “trying to keep one step ahead” of
cancer (Research Nurse 1), situating research as part of a wider process of mana-
ging a disease marked by uncertainty, evolution and mutation. This was elaborated
by one nurse consultant who was part of the leadership team for one of the initiat-
ives we studied:
… just understanding that the gene does this and therefore we can block it with this
…would be lovely if that was the end of the story but of course genes mutate and you
can have a mixed response within cancer as well…we also know that when we stop
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some of these drugs you can get a rebound of their cells growing again… So this has
been a whole new area of research over the last… years… it isn’t going to come to a
happy ending all of a sudden, it will form the basis of ongoing work that will extend
people’s lives…we hope for cure but where we can’t cure we hope to make it chronic
and manageable and this is one part of that armament really… . (Nurse Consultant 1)
Although the language of “armament” deploys a familiar war-based metaphor con-
cerning cancer (Sporn 1996), this was presented as a long war of attrition, framing
cancer as a resistant foe and genomic research as another staging post along the
way.
Interviewees also described how uncertainties could arise because of difﬁculties
with delivering complex genomic research protocols and other competing require-
ments to provide care to patients: tissue sampling was a particular issue here.
Samples were sometimes difﬁcult to obtain, especially if the patient was very
unwell or their tumor was difﬁcult to reach. Samples could also be very small
and be required for multiple (not just genomics) tests, becoming exhausted in the
process. But they were also important passports to novel targeted treatments
which might be life-saving, as well as important for the numerous research
studies seeking to pool and analyse genomic data to develop better diagnostics
and treatments for patients in the future. Interviewees told us their experiences of
navigating the practicalities of biopsy procedures and analysis could generate
uncertain results as in this excerpt from an interview with a pathologist:
It’s not the case that you’ve had a biopsy and you put it through a machine and you
get an answer that says, ‘yes you will or will not respond to a particular drug’. Often
there’s insufﬁcient material for testing, that means going back to rebiopsy patients
which is often inconvenient and potentially associated with risks and it doesn’t
necessarily give you a black and white answer. (Pathologist 2)
These accounts were common across our interviews with pathologists (and nursing
staff), particularly those involved in the two studies we followed as sample failure
had been an issue in both cases. This led them to downplay expectations of tissue
analysis, rendering it a provisional and precarious process.
Across these accounts, genomic research initiatives were situated as part of a
process of making cancer manageable, with practitioners acknowledging and
working with uncertainties as a way of keeping expectations of patients and
project leaders in check. In so doing, the interviewees sought to avoid the pitfall
of overpromising but at the same time signaled a commitment to these initiatives
as part of routine professional practice and the evolution of knowledge.
Interpretation, uncertainty and professional jurisdictions
We turn now to look more closely at how professionals spoke about the uncertain-
ties involved in interpreting genomic results with and for other professionals, focus-
ing on how their accounts sought to manage expectations about changing
professional roles and responsibilities, particularly for pathologists and geneticists.
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Echoing discourses about the deluge or slew of genomic data which can be found in
professional literatures (Prainsack 2017), these respondents expressed concerns
about how to interpret large quantities of genomic data and proceed to treatments
in the short-term because of a lack of guidelines on interpretation. So, whilst these
professionals accepted and foregrounded the uncertainties of cancer genomics as a
reason to lower expectations, as described in the previous section, they also
expressed a range of frustrations about how to work effectively in the absence of
certainty in the context of criticism and threats to their autonomy and jurisdictions.
As Fox writes:
The development of scientiﬁc medicine, then, has both uncovered and created
uncertainties and risks that were not previously known or experienced. Some of
these problems are so new, and raise such intricate and important questions of
fact, technique, judgment, authority, and values, that they cannot be quickly or
neatly resolved. The indeterminateness of these perplexing issues has contributed
to the sense of uncertainty about uncertainty, and augmented the sense of risk
about risk. (1980, 19)
For professionals involved in interpreting genomic data these uncertainties about
uncertainties were expressed in terms of frustrations centered around a lack of lit-
erature and guidelines for analysis, as captured below in the excerpt from an inter-
view with a consultant geneticist involved in the large-scale genomics medicine
initiative we studied:
In the short-term we don’t know what to do with the data… So… you do a genome
sequence on someone, there’s thousands and thousands of variants there. There’s not
enough evidence to know what to do with most of the results.… there aren’t the
downstream guidelines on what to do with the results. (Consultant Geneticist)
Concerns about a lack of evidence or literature as a basis for interpretation were
typically entangled with concerns about professional jurisdictions. These were
seen as being encroached or devalued in genomic research initiatives, the goal of
which is to mainstream the interpretation and delivery of genomic results. For
example, pathologists expressed concerns that the sheer volume of genomic data
deﬁed interpretation using standard, “human,” means, as in the excerpt below:
… one concern which is not so much for me but if I was starting off was that I’d actu-
ally be made redundant by all of this (laughs)… because you will get certain people
that preach that we don’t need any interpretive [skills] you just chuck it in a black box
and get a result and that’s all you need. So it removes… the human… . I hate to cast
aspersions but you see a lot of genetics laboratories, they must have the best kit, the
new test… they’re very good at doing the test but they have no idea about the context
… the beauty of a place like this is it considers all the elements and puts it in a clinical
context rather than just hiving it off to a laboratory anywhere… [we need to] make
sure it evolves the right way and it’s still embedded in a clinical service… because
without that interaction the development will grind to a halt because you won’t
have input from different perspectives, which is important. (Pathologist 3)
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For this pathologist there was a danger that uncertainties around how to interpret
results could be resolved or side-stepped by automation or analysis-at-a-distance
from the clinic, creating a sense of “displacement” (Bourret, Keating, and Cambro-
sio 2011) and uncertainty about the decline of the profession and their working
arrangements with other clinicians. This elicited an account of the importance of
pathology services best embedded in a clinical environment to produce better
kinds of interpretation of results: akin to the bio-clinical collective described by
Bourret, Keating, and Cambrosio (2011). The importance of pathologists with a
keen scepticism about the limits of clinical interpretation working alongside gen-
etics and clinical scientists to “provide clinical oversight about the appropriateness
of some of the clinical interpretations” was also stressed:
… other centres will offer blanket clinical interpretations which may not necessarily
be appropriate and the problem is oncologists act on those clinical interpretations
[especially] if you’re a busy general oncologist working in a smaller hospital
you’re not necessarily up to speed with all the evidence… then you may take at
face value the clinical interpretation attached to these reports. (Pathologist 2)
Here the capacity of professional groups such as pathologists and clinical geneti-
cists to deliver genomic medicine was asserted on the basis of their expertise in
recognizing and managing uncertainty, including their ability to identify the need
for appropriate kinds of support in the form of guidelines, literature and multidis-
ciplinary working to mediate that uncertainty. Through these kinds of accounts
practitioners with a track record of interpreting clinical data and delivering diag-
noses sought to rework the expectations of genomics transforming services in
such a way that they could play a key part in its delivery. As Latimer et al.
(2006, 599) noted, “moments of ambiguity and deferral create an imperative
space that helps legitimate the need for more technoscience, and consequently,
more clinical judgment with which to ﬁx the genetic future.”
Geneticists also spoke to us about the need to recalibrate the expectations of treat-
ing physicians who wanted more certainty from genomic results than they could
provide as captured in the excerpt below:
So we quite often send reports out saying, well we’ve seen this… at the moment
there’s no literature available to indicate that it’s pathogenic… and that’s our best
guess to evidence that.…And for us we think we’ve done as much as we can and
the clinician phones: ‘what does this mean?’. (Cytogeneticist)
As in Timmermans’ (2015)’ study of exome sequencing and Variants of Unknown
Signiﬁcance, managing uncertainties around matching genotype and phenotype
was exacting work (Timmermans, Tietbohl, and Skaperdas 2017). In the words
of another pathologist, reports are “not always as tidy as is sometimes portrayed
in the media,” and they can be disappointing, when, for example, results only
provide information about patients who are unlikely to respond to particular treat-
ments rather than the ones that are likely to respond – offering “negative predictors,
not positive solutions.” Here pathologists and geneticists articulated their key role
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in mediating uncertainties in pressurized working environments which sometimes
resulted in tension with other clinicians’ expectations.
The difﬁculties of meeting clinicians’ expectations of support with interpreting
genomic results in conditions of interpretive uncertainty was also highlighted in
relation to new pressures on workload, as in the excerpt below:
… there’s an increasing tendency for other labs and research groups to have access to
genetic testing… I got an email the other day from a Haematologist saying, ‘I’ve got
a patient. I think they’ve got this condition. It’s all a bit odd. They’ve had some testing
through some sort of semi-research study. They’ve found something, here’s the
report, what do you think?’ And it becomes clear that actually the people who’ve
done the test don’t fully understand what they’ve done… or what to do with the
results (laughs).… so you know we’re kind of picking up the pieces in Genetics
…which creates more work, and of course that work is not funded… [it gets even
more difﬁcult] when someone might have access to a whole exome or genome
panel and they’ve not actually worked in a genetics service and the probability of
them ﬁnding something and they don’t know what to do with it, it just goes up…
they’re going to ﬁnd loads of things. And they’re going to go, ‘Oh, hang on,
phone a friend!’. (Consultant Geneticist)
This excerpt illustrates the difﬁculties this geneticist was navigating with respect to
his service and professional role in the context of genomic data – here this respon-
dent ﬂags the ad hoc kinds of research and consultations that are being requested as
genomics enters the clinic, asserting his epistemic authority in the context of chal-
lenges posed to their service by developing expertise elsewhere. He also ﬂags the
difﬁculties of providing specialist input whilst experiencing budget constraints,
further emphasizing concerns about the devaluing of expertise alongside the chal-
lenges to professional jurisdiction that genomics might pose.
In this section, we have explored a range of professional accounts of the challenges
and difﬁculties of interpreting and providing genomic data, including for other clin-
icians. Accounts stressed the complexities and provisional aspects of analysis and
emphasized the importance of appropriately resourced, integrated patient-centered
services as a way to manage uncertainties appropriately, and as a counter to the
threat of automation, de-professionalisation and outsourcing. Echoing the ﬁndings
of Timmermans (2015; Timmermans, Tietbohl, and Skaperdas 2017), Bourret,
Keating, and Cambrosio (2011) and Haase, Michie, and Skinner (2015), pro-
fessionals gave accounts of evolving local forms of best practice, in this case pre-
mised on integrated and bespoke services, carving out a kind of “local universality”
(Timmermans and Angell 2001) in the face of concerns about de-skilling and
centralization.
Difﬁcult conversations with patients
In this section, we turn to look more closely at how doctors and nurses accounted
for uncertainties around genomic research and data when interacting with patients.
232 A. Kerr et al.
We found that oncologists concurred with pathologists’ and geneticists’ accounts
of clinicians ﬁnding uncertainty problematic as outlined above, as in the excerpt
below from one of the leading proponents of genomic research in the institution:
… so you get into a situation where you’ve actually got to know something about the
constellation of problems that the patient had got in order to know which is the par-
ticular drug that’s effective.… you could easily imagine the situation where it
becomes too complicated for your everyday oncologist to be able to handle it…
[or] where its actually too complicated for a human being to understand it…my
top line vision is that this is coming, I wouldn’t get into this kind of conversation
with anybody other than somebody who really got it about genomics. Because I
think it’s frightening… all this complexity is actually frightening to clinicians who
love order and control (laugh). And to patients as well of course, who want some
control over their destiny as well. (Oncologist 1)
In addition to invoking the threat of automation, this oncologist notes that genomic
complexity could amplify unwelcome uncertainties and noted how unsettling this
could be for “everyday” practitioners and patients, framing genomic appreciation
and understanding as a kind of elite forward-looking activity. Another senior inter-
viewee, tasked with leading a major genomic sequencing initiative in the region,
also framed (other) clinicians’ reservations about genomic information in the
clinic as a feature of an established “medical culture”:
a signiﬁcant group of people see certainty in information, it gives much more precise
details of what’s going to happen to a patient, is actually something they’d rather not
know… it’s easier if you’ve got a 95% chance of being cured, but if you say to
someone ‘actually we know from this data that this is just not going to work’ then
that’s something people reject. Because if you open the box then you get the infor-
mation. If you don’t do it in the ﬁrst place you just carry on regardless.… people
actually see personalised medicine as something potentially very, very difﬁcult…
particularly what you do when the data shows that somebody really isn’t going to
recover and there’s nothing you can do for them… people… [are] quite prepared
to crack on with treatment… just for the sake of doing something… . (Clinical
Director 1)
Here opening the black box (using genomic technologies that the ﬁrst of our inter-
viewees above describes as “a bit science ﬁction”) could generate unwelcome kinds
of certainty about treatments not being effective, and in contrast to the previous
account, shutting down the possibility of “just carrying on regardless.”
The difﬁculty of navigating the ampliﬁcation of unwelcome un/certainties for
patients resulting from genomic data was a recurring theme across our interviews
with clinicians. Handling the uncertainties of results, treatment decisions and
further options in dialogue with patients and families is a major part of cancer prac-
titioners’ work, often involving lengthy complex and sometimes highly technical
discussions, together with a keen sense of what kinds of information and choices
are appropriate for sharing at what points in the process. Genomics was framed
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as bringing added complexity to these tasks and accounts of how clinicians would
have to carefully navigate this as part of their research and care (see also Latimer
et al. 2006; Haase, Michie, and Skinner 2015). As we now go on to explore, the
cancer clinicians we interviewed advocated patient-centered management of uncer-
tainty to manage expectations and protect the integrity of their clinical judgement
and expertise (Broom, Adams, and Tovey 2009).
The commitment to patient-centered management of genomic uncertainty
emerged in a range of accounts, often focused on how best to deliver results to
patients. As one clinician scientist with expertise in skin cancer, where genomic
analysis is already an established as part of treatment-decision making,
commented:
It’s possible to really distress patients by forcing data on them that they really don’t
want. You know, some people just do not want to know a percentage, they don’t want
it.… it’s my belief anyway that you have to ﬁnd out how much information your
patient wants and needs and give them every access to it… But everyone’s different.
(Clinician Scientist)
Too much information, be that survival statistics or genomic data, was presented as
a recipe for confusion and anxiety. But for other patients, practitioners argued that
too little information could cause anxiety. This is echoed in the excerpt below,
where an oncologist specializing in gynaecological cancers involved in a number
of trials of molecular analysis, framed genomics as presenting clinicians with the
challenge of working out what information to share with patients:
… I think the patients have been amazingly receptive and understanding… you
know, ‘We’ve had a look at 592 genes and proteins and these are the genes that
have got the abnormalities and this means this and this means that’ is a conversation
they’ve largely been capable of listening to with interest.… [But] some patients [say]
‘Well that’s all detailed nonsense, I don’t really understand. What do you think I
should do next?’ and they’re quite happy for me to do all the interpretation… The
real challenge is working out how much the patient wants to know and then giving
them the right information that’s right for them because the right information for
one patient is not the right information for the next one. (Oncologist 2)
This need to manage expectations through tailored provision of more detailed
layers of information, is a form of personalization with which cancer clinicians
are already very well versed. But in these accounts, they spoke of how genomics
intensiﬁed these processes, and brought with it the need to develop new ways of
simplifying information, as this oncologist went on to describe:
… I don’t think it necessarily means more face-time…We’ve moved beyond the
days of ‘You’ve got x cancer and therefore you need to have this drug’. I would
say, ‘We’ve looked in detail and for your particular type of cancer then we think
the right thing to do is this’. Now if somebody said to me, ‘What do you mean,
my type of cancer?’ then I would be happy to explain that. But I don’t actually go
through… ’We used to think it was x cancer now we recognise its three things,
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actually those three things could probably be 20 things and those 20 things have now
got 1000 individual genetic mutations, so let me take you through the 20,000 possi-
bilities of what it could be… ’ I would just say, the information we have about your
cancer means this is the right thing for you… that’s what the patient wants to hear,
‘we know more and more about you which enables us to focus our treatment more
and more on you as an individual’. (Oncologist 2)
In this excerpt, although the oncologist begins by saying these developments will
not necessarily lengthen consultations, the account suggests that, when patients do
ask questions, further efforts to tailor information are necessary to provide
reassurance.
Genomic research was also framed as generating new kinds of clinical work in
handling disappointments and misunderstandings about the potential for cure
which the discourse of precision can generate, particularly since experimental
trials can fail as a research nurse involved in a clinical trial in lung cancer explained:
… one of the things we’re having to talk about… is we will understand some of the
information we get and we don’t understand some of the other information we get.…
I think a lot of our talk now is about how this is going to enhance care, but what
about the people who get no useful information back, or the testing fails? (Research
Nurse)
Practitioners spoke about having to carefully navigate what kinds of un/certainties
participation in research, including trials, could bring to patients, which at times
meant downplaying the prospects of certainty and maintaining the possibility of
uncertainty and failure given their experimental nature. For example, an oncologist
spoke about the need to downplay patients’ expectations of immediate success
whilst also cultivating hopefulness about the option of future molecular treatments
on trial arms. This came up in discussions about the initial consultation about invol-
vement in the trial:
So we’ll go through about 4 or 5 scenarios and by that stage they’re absolutely satu-
rated [with information]… so we will mention the genomic medicine trial, ‘we’re
doing this study which doesn’t involve anything else apart from blood tests. It’s
looking for a potential treatment. You may or may not be eligible for it’. So, it’s a
sort of loose conversation… it’s not a focus because it’s not a ﬁrst line treatment.
(Oncologist 4)
Concerns about managing patient expectations also arose in relation to handling
results that might show that some of the latest treatments would not be effective
on a patient’s cancer, as an oncologist with expertise in genomic analysis in the
treatment of lung and breast cancer patients commented:
they’d been given a hope… , that science would come to the rescue. You know, and
not just a… vague hope, but a very kind of targeted precise hope… that genomics
was going… to save the day for them.… that’s doubly difﬁcult for patients… to
know that genomics isn’t going to save the day and that there’s no treatment for
you and that your life expectancy by necessity…will be shortened. (Oncologist 1)
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Here genomic results to do not deliver a targeted treatment are presented as having
the potential to make things “doubly difﬁcult” because of the disappointments that
can accrue when expectations are not met.
In these discussions, practitioners foregrounded the work involved in navigating
the complexity and uncertainties of genomics when caring for patients and mana-
ging their expectations. Practitioners told us about how genomic research intensi-
ﬁed the complex work involved in navigating how much of what kind of
information and opportunities to share with patients at what points in their treat-
ment and for what kinds of patients. Lowering expectations (Gardner, Samuel,
and Williams 2015) and “tinging” their encounters with vulnerable patients with
uncertainty (Moreira 2010) about the prospects of genomic research were part of
their practices of care.
Discussion and conclusion
Genomics research is increasingly embedded in cancer care. In this article, we have
explored how professionals account for uncertainty in the course of managing
expectations about what this research can deliver for patients and services more
generally. Our analysis has revealed three interconnected kinds of “uncertainty
work” (Star 1985) involved in cancer professionals’ encounters with genomic
research. First, we demonstrated how reﬂection on the un/certainties revealed in
genomic research about cancer, are part of their articulations of an ethos of
modest, persistent inquiry which is linked to their cautious support for genomic
research and innovation which also seeks to lower expectations about what this
new ﬁeld can deliver in clinical care. We also explored “uncertainty about uncer-
tainty” in relation to interpretation of genomic results. Here we focused in particular
on pathologists’ and geneticists’ concerns about the implications of genomics for
their autonomy and jurisdictions, via the articulation of their role in bioclinical col-
lectives (Bourret, Keating, and Cambrosio 2011) that integrated patient-centered
care and their important role in resolving clinical uncertainties. In so doing prac-
titioners were engaged in recalibrating other professionals’ and project leaders’
expectations about what can be delivered by genomic research and securing their
place in the genomic medicine of the future. In the ﬁnal section we considered
how the uncertainties of genomic research intensiﬁed clinicians’ work of managing
patients’ expectations through tailoring and personalizing their treatments and
research involvement. We discussed how this involved the cultivation of an exper-
imental ethos amongst patients, and the careful navigation of un/welcome kinds of
un/certainty generated by too much and too little genomic information arising from
their participation in trials.
Through this study we have shown, as genomic research and care develop in the
cancer clinic, professionals articulate a range of uncertainties as part of their efforts
to recalibrate patient, practitioner and institutional expectations of its prospects. In
so doing professionals like pathologists and clinical geneticists are crafting a place
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for themselves in genomic medicine research and the services of the future, based
on their extensive capabilities and experience in navigating other professionals’
expectations of genomics. Oncologists and nurses are also articulating a role for
themselves based on their expertise in patient-centered tailoring of genomic infor-
mation as part of managing patient expectations. Together these practitioners also
appeal to the intrinsic uncertainties of cancer as a means by which to moderate
expectations of genomic research and innovation at the same time as supporting
these initiatives as part of their commitment to scientiﬁc progress. As such these
types of professional uncertainty work are a key feature of managing expectations
at the intersections of genomic research and clinical care.
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